CP.TO 1.15VRT -18.06NVDA -7.33TSM -15.23JPM -6.1ZST.TO 0.01HSAV.TO -0.03HSUV.U.TO 0.03
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.75
+0.03 (0.11%)
as of Sep 14, 2026, 5:42:20 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY

Pfizer Inc(PFE)

May 17, 2001
Prefers over Merck. No patent expiries.
Photo of John McCollJohn McCollUnlock Rating
$44.76

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

May 16, 2001
(Was a top pick on Apr 27/00 up 3.3%) Still likes.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$44.62

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

May 10, 2001
Great pipeline of drugs. Good synergies. Safe play. Price a little high.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$43.74

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

May 04, 2001
At a good price now. Good pipeline.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$43.46

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 03, 2001
At fair market value. Now ($45). No room to grow.
Photo of Ross HealyRoss HealyUnlock Rating
$42.25

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 25, 2001
(Was a top pick on Jan 8 down 3%) Still likes. Just bought more. Has the least amount of patent expiries.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$40.91

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Apr 12, 2001
Long term. Strong growth/company.
Photo of Neil MurdockNeil MurdockUnlock Rating
$40.70

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 10, 2001
High quality and fast growth. A little too high now.
Photo of Jeff MorrisonJeff MorrisonUnlock Rating
$41.00

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 04, 2001
Good pipeline. Good defensive play.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$39.75

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 27, 2001
Going through some problems.
Photo of David DriscollDavid DriscollUnlock Rating
$39.98

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Mar 23, 2001
Great Products. Good mngmnt. At a good price. Best company in the pharmaceutical space. Great cash flow
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$37.53

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 22, 2001
Great business model. Good pipelines. At a good price now.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$35.67

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 12, 2001
Excellent long term hold. Good drugs in the pipeline
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$40.35

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 07, 2001
Not cheap, but good growth. Good holdings on patents.
Photo of David McLeanDavid McLeanUnlock Rating
$41.95

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 06, 2001
Has done well until recently. Drug stocks in US are extended now. Will tech sell off move into drug sector?
Photo of Ross HealyRoss HealyUnlock Rating
$43.10

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 871 to 885 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

DML.TO -0.18$4.01
BIR.TO 0.06$6.38
M 1.025$23.105
ZRE.TO 0.09$22.46
HMAX.TO -0.02$17.51

Today's Top Picks

CP.TO 1.15$124.99
VRT -18.06$239
NVDA -7.33$210.96
TSM -15.23$418.01
JPM -6.1$350.13

Popular Articles

Latest Sell Signals

XRE.TO 0.05$15.73
ORCL -5.49$144.79
ORCL -5.49$144.79
URI 8.38$997.5
BBD.B.TO 8.2$309.02

Most Recent Experts

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like